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NHS monthly costs between overweight (47€), mild (128€),
moderate (162€) and severe (205€) obese subjects was signiﬁcant
(P = 0.02, Kruskall Wallis test). We found no statistically signif-
icant difference in out-of-pocket costs (P = 0.52). CONCLU-
SIONS: In few years the cost for the health care management of
a cohort of more than 5 millions of obese plus 15 millions of
overweight individuals in Italy is likely to become unbearable for
the I-Nhs, as it will be for most health systems. Policy makers
should give the highest priority to the identiﬁcation, promotion
and implementation of effective integrated programmes for the
prevention of obesity and overweight.
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OBJECTIVES: The health service impact of obesity is growing
relentlessly. There exist a small number of medical treatments 
for obesity. Obesity results in an increased risk of a plethora of
diseases. The purpose of this study was to evaluate the cost-
utility of orlistat (Xenical) in the UK. METHODS: A stochastic
simulation model was constructed using clinical trial and real-
life data comparing orlistat with no treatment and placebo under
various scenarios. The time duration was 2-years, 2003 prices
(UK£), costs discounted at 6%, beneﬁts 11/2% and evaluated
from an NHS perspective. Events were determined for only 
cardiovascular (CV) disease end points, and determined by
various risk functions. Utility was gained by a direct reduction
in obesity, survival and progression to CV events, including
microvascular events for diabetes. Costs were summed for events
and maintenance therapies. Extensive statistical economic analy-
sis and sensitivity analysis was undertaken. RESULTS: The cost
per quality adjusted life year (QALY) for orlistat versus no
treatment evaluating National Institute for Clinical Ecxellence
(NICE) guidelines was £12,814. The cost per QALY for orlistat
versus no treatment evaluating the product license was £13,045.
The cost per QALY for orlistat versus placebo evaluating 
NICE guidelines was £19,128. The cost per QALY for orlistat
versus no treatment evaluating the product license was £17,386.
These ﬁndings were fairly insensitive to variation in the main
parameters. CONCLUSIONS: These data, from a conservative
evaluation of the cost-utility of orlistat, showed that the treat-
ment is well within the cost-effectiveness threshold set by 
NICE (£20,000/QALY and £30,000/QALY). This analysis con-
tinues to support the positive guidance made by NICE in 2001
on orlistat.
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OBJECTIVES: Purpose of this study was to evaluate quality of
life (QoL) changes in MAP patients treated with orlistat accord-
ing to the product licence. Orlistat, a clinically-effective, cost-
effective treatment for weight reduction, is endorsed by NICE.
MAP, the patient support programme, is endorsed by the UK
Medicines Partnership project and provides direct support
through trained health care professionals to patients treated with
orlistat. METHODS: Patients starting treatment with orlistat
and enrolled in the MAP programme were recruited into this
study. Quality of life was measured using the 31-item, disease-
speciﬁc IWQOL-Lite: Impact of Weight on Quality of Life ques-
tionnaire comprising ﬁve scales assessing physical function,
self-esteem, sexual life, public distress, work and a total score.
Weight, height and body mass index (BMI) were also collected
at baseline, 3 and 6 months. Effect Size (ES) and Standardized
Response Means (SRM) were used to assess clinically meaning-
ful change for IWQOL-Lite subscales and total score, with values
interpreted as small (0.20–0.50), moderate (0.51–0.80) and large
(> = 0.81). RESULTS: All patients (n = 133) who achieved a
weight reduction of at least 5% at 3 months as stipulated by the
product licence were included in the analyses. Results of this
study showed that these patients achieved clinically meaningful
changes from baseline across all disease-speciﬁc QoL subscales,
with moderate changes from baseline in physical function (ES =
0.61; SRM = 0.77), and moderate to large changes from base-
line in self-esteem (ES = 0.66; SRM = 0.91) and IWQOL-Lite
total score (ES = 0.70; SRM = 0.94). CONCLUSIONS: These
ﬁndings clearly demonstrate that a weight reduction of at least
5% in patients taking orlistat enrolled in the MAP programme
translates into clinically signiﬁcant improvements across all
disease-speciﬁc QoL domains. It can therefore be concluded that
a combination of effective treatment with orlistat and direct
patient support provided by health care professionals through
the MAP programme results in clear beneﬁts for these patients.
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OBJECTIVES: Obesity increases the risk of chronic diseases,
with consequences on social cost and Quality of Life (QoL). Our
objective was to estimate the social cost and QoL in overweight,
obese and severe obese people. METHODS: A Cost-of-Illness
study was conducted from the societal perspective, adopting
three-month retrospective observational period. Data were col-
lected from a population based naturalistic survey investigating
cardiovascular risk factors in adult (40–79y.o.) Italian general
population. We selected normal weight people as control group
(Body Mass Index, BMI = 18.5–24.9), overweight (BMI =
25.0–29.9), obese (BMI = 30.0–34.9) and severe obese (BMI >
35.0) people, interviewed by general practitioners on
clinical/demographic characteristics, direct costs (drugs, hospi-
talisations, specialist visits, diagnostics exams) and indirect costs
(productivity loss). QoL was evaluated with the EQ-5D ques-
tionnaire. RESULTS: Data from 620 people were analyzed
(mean age = 58.2, 46.5% men). Total cost in overweight, obese
or severe obese people was quantiﬁed as twice than in normal
weight people (>200 vs. 111€/person/month). Direct cost
involved more than half of total expense: hospitalizations
accounted for the greatest part of direct cost, followed by drugs,
diagnostic exams, medical visits and laboratory exams. Globally,
the Visual Analogue Scale mean score was higher in overweight
than in normal weight people, and lower in obese and severe
obese people. Most of people reported no problem in “mobil-
ity”, “self care” and “usual activities” (around 90%), with
“pain/discomfort” and “anxiety/depression” (around 50%).
Very few people (<5%) reported extreme problems in any
